RUNX2 and chronic kidney disease: Recent studies have confirmed (2022 J Clin Invest article) that, in both in vivo and in vitro CKD models, RUNX2 promotes osteoblast differentiation (Li et al. 2022) and also inhibits osteoclast generation (Xin et al. 2020).